Price
$7.23+30.74%Social Signal Score
Analyst Ratings
16 analystsRevenue
$54.98M+12.23%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helen Sabzevari
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
- Beta
- 1.02
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -6.91
Financials
Revenue
$54.98M+12.2%Net Income
$20.07MEBITDA
$23.02MFree Cash Flow
$-18.20MEPS (diluted)
$0.05Shares Outstanding (diluted)
413.69M+249.6%Operating Expenses
$29.53MCash & Debt
$38.21MReturn of Capital
$1.50MRevenue by Segment (annual)
$3.92MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.68M | $-250.64M | $-1.41 |
| 2024 | $3.92M | $-126.23M | $-0.47 |
| 2023 | $6.22M | $-95.90M | $-0.39 |
| 2022 | $26.91M | $28.32M | $-0.33 |
| 2021 | $14.27M | $-92.17M | $-0.47 |
| 2020 | $31.99M | $-170.52M | $-1.02 |
| 2019 | $31.99M | $-170.52M | $-1.35 |
| 2018 | $160.57M | $-509.34M | $-3.93 |
| 2017 | $230.98M | $-117.02M | $-0.98 |
| 2016 | $190.93M | $-186.61M | $-1.58 |
| 2015 | $173.60M | $-84.49M | $-0.76 |
| 2014 | $71.93M | $-81.82M | $-0.83 |
| 2013 | $23.76M | $-38.98M | $-0.95 |
| 2012 | $13.93M | $-81.87M | $-14.80 |
Valuation
PGENhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (11)
- Newszacks.com·20h ago·Neutral
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
View source ↗ - Newszacks.com·5d ago·Neutral
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newszacks.com·5d ago·Neutral
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
… its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.
View source ↗ - Newszacks.com·11d ago·Neutral
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
View source ↗ - Newsprnewswire.com·15d ago·Negative
…ccelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the …
View source ↗ - Newszacks.com·21d ago·Positive
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
View source ↗ - Newszacks.com·25d ago·Neutral
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
View source ↗ - Newszacks.com·46d ago·Positive
Reasons Why Investors Should Consider Betting on PGEN Stock Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.
View source ↗ - Newszacks.com·52d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsseekingalpha.com·59d ago·Negative
Precigen: Has To Grow Into Its Valuation Precigen surged 266% on PAPZIMEOS FDA approval but now trades at a premium valuation near $2.24 billion. PAPZIMEOS, the sole revenue driver, reached $53.1 million in Q2 with COGS being just around $2.8 million. PGEN's pipeline faces stiff competition, with most candidates showing weaker efficacy than approved or late-stage rivals.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $0.09 per share
Typical surprise +33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.05 vs $-0.01beat
- Wed, May 13$-0.02 vs $-0.03beat
- Wed, Mar 25$-0.07 vs $-0.10beat
- Thu, Nov 13$-1.06 vs $-0.08miss
- Tue, Aug 12$-0.11 vs $-0.09miss
- Wed, May 14$-0.18 vs $-0.08miss
Estimates and results for PGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PGEN officers and directors.
- Bought
- $25k
- Sold
- $23.7m
1 trade
27 trades
- Kindler Jeffrey Bsold
- Shah Rutul Rsold
- Tennant Philsold
- Agee Nancy Hbought
- Shah Rutul Rsold
- Shah Rutul Rsold
- Shah Rutul Rsold
- Thomasian Harry Jr.sold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PGEN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.